Literature DB >> 33461558

Doxorubicin treatment modulates chemoresistance and affects the cell cycle in two canine mammary tumour cell lines.

Michela Levi1, Roberta Salaroli1, Federico Parenti1, Raffaella De Maria2, Augusta Zannoni1, Chiara Bernardini1, Cecilia Gola2, Antonio Brocco1, Asia Marangio1, Cinzia Benazzi1, Luisa Vera Muscatello1, Barbara Brunetti1, Monica Forni1, Giuseppe Sarli3.   

Abstract

BACKGROUND: Doxorubicin (DOX) is widely used in both human and veterinary oncology although the onset of multidrug resistance (MDR) in neoplastic cells often leads to chemotherapy failure. Better understanding of the cellular mechanisms that circumvent chemotherapy efficacy is paramount. The aim of this study was to investigate the response of two canine mammary tumour cell lines, CIPp from a primary tumour and CIPm, from its lymph node metastasis, to exposure to EC50(20h) DOX at 12, 24 and 48 h of treatment. We assessed the uptake and subcellular distribution of DOX, the expression and function of P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP), two important MDR mediators. To better understand this phenomenon the effects of DOX on the cell cycle and Ki67 cell proliferation index and the expression of p53 and telomerase reverse transcriptase (TERT) were also evaluated by immunocytochemistry (ICC).
RESULTS: Both cell lines were able to uptake DOX within the nucleus at 3 h treatment while at 48 h DOX was absent from the intracellular compartment (assessed by fluorescence microscope) in all the surviving cells. CIPm, originated from the metastatic tumour, were more efficient in extruding P-gp substrates. By ICC and qRT-PCR an overall increase in both P-gp and BCRP were observed at 48 h of EC50(20h) DOX treatment in both cell lines and were associated with a striking increase in the percentage of p53 and TERT expressing cells by ICC. The cell proliferation fraction was decreased at 48 h in both cell lines and cell cycle analysis showed a DOX-induced arrest in the S phase for CIPp, while CIPm had an increase in cellular death without arrest. Both cells lines were therefore composed by a fraction of cells sensible to DOX that underwent apoptosis/necrosis.
CONCLUSIONS: DOX administration results in interlinked modifications in the cellular population including a substantial effect on the cell cycle, in particular arrest in the S phase for CIPp and the selection of a subpopulation of neoplastic cells bearing MDR phenotype characterized by P-gp and BCRP expression, TERT activation, p53 accumulation and decrease in the proliferating fraction. Important information is given for understanding the dynamic and mechanisms of the onset of drug resistance in a neoplastic cell population.

Entities:  

Keywords:  BCRP; Canine mammary tumour; Cell cycle; Cell line; Chemoresistance; Doxorubicin; P-glycoprotein; Proliferation index; Telomerases; p53

Mesh:

Substances:

Year:  2021        PMID: 33461558      PMCID: PMC7814552          DOI: 10.1186/s12917-020-02709-5

Source DB:  PubMed          Journal:  BMC Vet Res        ISSN: 1746-6148            Impact factor:   2.741


  76 in total

1.  Immunocytochemical detection of the p170 multidrug resistance (MDR) and the p53 tumor suppressor gene proteins in human breast cancer cells: clinical and therapeutical significance.

Authors:  B Bodey; B Bodey; A M Gröger; J V Luck; S E Siegel; C R Taylor; H E Kaiser
Journal:  Anticancer Res       Date:  1997 Mar-Apr       Impact factor: 2.480

2.  Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model.

Authors:  Lili Bao; Aliyya Haque; Kamilah Jackson; Sidhartha Hazari; Krzysztof Moroz; Rachna Jetly; Srikanta Dash
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

3.  Doxorubicin pathways: pharmacodynamics and adverse effects.

Authors:  Caroline F Thorn; Connie Oshiro; Sharon Marsh; Tina Hernandez-Boussard; Howard McLeod; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-07       Impact factor: 2.089

Review 4.  ABC efflux pump-based resistance to chemotherapy drugs.

Authors:  Paul D W Eckford; Frances J Sharom
Journal:  Chem Rev       Date:  2009-07       Impact factor: 60.622

Review 5.  The role of ABC transporters in drug resistance, metabolism and toxicity.

Authors:  Hristos Glavinas; Péter Krajcsi; Judit Cserepes; Balázs Sarkadi
Journal:  Curr Drug Deliv       Date:  2004-01       Impact factor: 2.565

6.  Dose- and time-dependent effects of doxorubicin on cytotoxicity, cell cycle and apoptotic cell death in human colon cancer cells.

Authors:  Regine Lüpertz; Wim Wätjen; Regine Kahl; Yvonni Chovolou
Journal:  Toxicology       Date:  2010-03-25       Impact factor: 4.221

7.  Micronuclei Frequency in Tumors Is a Predictive Biomarker for Genetic Instability and Sensitivity to the DNA Repair Inhibitor AsiDNA.

Authors:  Wael Jdey; Sylvain Thierry; Tatiana Popova; Marc-Henri Stern; Marie Dutreix
Journal:  Cancer Res       Date:  2017-06-06       Impact factor: 12.701

8.  Evaluation of telomerase in canine mammary tissues by immunohistochemical analysis and a polymerase chain reaction-based enzyme-linked immunosorbent assay.

Authors:  Serena Panarese; Barbara Brunetti; Giuseppe Sarli
Journal:  J Vet Diagn Invest       Date:  2006-07       Impact factor: 1.279

9.  Immunohistochemical Expression of P-glycoprotein and Breast Cancer Resistance Protein in Canine Mammary Hyperplasia, Neoplasia and Supporting Stroma.

Authors:  M Levi; B Brunetti; G Sarli; C Benazzi
Journal:  J Comp Pathol       Date:  2016-08-12       Impact factor: 1.311

10.  Expression and role of PGP, BCRP, MRP1 and MRP3 in multidrug resistance of canine mammary cancer cells.

Authors:  Karol M Pawłowski; Joanna Mucha; Kinga Majchrzak; Tomasz Motyl; Magdalena Król
Journal:  BMC Vet Res       Date:  2013-06-17       Impact factor: 2.741

View more
  1 in total

1.  Functional Expression of Multidrug-Resistance (MDR) Transporters in Developing Human Fetal Brain Endothelial Cells.

Authors:  Phetcharawan Lye; Enrrico Bloise; Guinever E Imperio; David Chitayat; Stephen G Matthews
Journal:  Cells       Date:  2022-07-21       Impact factor: 7.666

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.